Cadence Neuroscience Inc.

Cadence Neuroscience Inc. is a groundbreaking startup in the health care industry, dedicated to revolutionizing epilepsy treatment through a unique neuromodulation approach. Since its establishment in 2017, the company has garnered attention for its innovative methods and has recently received a significant boost with a $26.03M Series B investment on 28 February 2023. This investment comes from a diverse group of prominent investors including F-Prime Capital, Angelini Ventures, Jazz Venture Partners, Mayo Clinic, LivaNova, Angelini Lumira Biosciences Fund. With its headquarter in the United States, Cadence Neuroscience is well-positioned to further develop and implement its pioneering therapy. This recent investment not only underscores the confidence of renowned organizations but also signifies the potential impact of Cadence Neuroscience's approach in the field of neuromodulation. As the company continues to advance, it is poised to make significant contributions to epilepsy treatment and beyond, making it an attractive prospect for venture capital involvement.